The stock of NewLink Genetics Corp (NASDAQ:NLNK) is a huge mover today! About 290,395 shares traded hands. NewLink Genetics Corp (NASDAQ:NLNK) has declined 26.18% since March 2, 2016 and is downtrending. It has underperformed by 34.44% the S&P500.
The move comes after 5 months positive chart setup for the $463.46 million company. It was reported on Oct, 5 by Barchart.com. We have $39.49 PT which if reached, will make NASDAQ:NLNK worth $662.75M more.
Analysts await NewLink Genetics Corp (NASDAQ:NLNK) to report earnings on November, 1. They expect $-0.62 earnings per share, down 12.73% or $0.07 from last year’s $-0.55 per share. After $-1.12 actual earnings per share reported by NewLink Genetics Corp for the previous quarter, Wall Street now forecasts -44.64% EPS growth.
NewLink Genetics Corp (NASDAQ:NLNK) Ratings Coverage
Out of 2 analysts covering NewLink Genetics (NASDAQ:NLNK), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. NewLink Genetics has been the topic of 2 analyst reports since March 23, 2016 according to StockzIntelligence Inc. The rating was downgraded by SunTrust on Wednesday, May 11 to “Neutral”. The stock of NewLink Genetics Corp (NASDAQ:NLNK) has “Outperform” rating given on Wednesday, March 23 by Robert W. Baird.
According to Zacks Investment Research, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.”
Insitutional Activity: The institutional sentiment decreased to 0.73 in Q2 2016. Its down 0.18, from 0.91 in 2016Q1. The ratio turned negative, as 34 funds sold all NewLink Genetics Corp shares owned while 32 reduced positions. 11 funds bought stakes while 37 increased positions. They now own 14.35 million shares or 17.92% less from 17.49 million shares in 2016Q1.
Panagora Asset Mngmt reported 1,675 shares or 0% of all its holdings. First Eagle Invest Ltd Liability Company holds 0.06% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK) for 2.19 million shares. Renaissance Ltd Liability, a New York-based fund reported 815,500 shares. Blackrock Fund Advsrs has invested 0% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK). Cornerstone Capital Management Limited Liability Company last reported 0% of its portfolio in the stock. Deutsche Bank & Trust Ag accumulated 0% or 338,285 shares. Legal And General Group Public Ltd Limited Liability Company reported 3,623 shares or 0% of all its holdings. Hap Trading Limited Liability Company reported 227,728 shares or 0.15% of all its holdings. Alliancebernstein L P last reported 0% of its portfolio in the stock. Pnc Fincl Services Grp has invested 0% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK). Globeflex Cap L P owns 34,934 shares or 0.11% of their US portfolio. Stifel Corp accumulated 0% or 12,400 shares. Moreover, Blackrock Advsr Lc has 0% invested in NewLink Genetics Corp (NASDAQ:NLNK) for 37,436 shares. Quantbot Techs Limited Partnership owns 756 shares or 0% of their US portfolio. Raymond James Assoc has 15,320 shares for 0% of their US portfolio.
More notable recent NewLink Genetics Corp (NASDAQ:NLNK) news were published by: Seekingalpha.com which released: “NewLink Genetics Has Many Near-Term Catalysts” on September 27, 2016, also Fool.com with their article: “Why NewLink Genetics Corporation Dropped 27.6% in May” published on June 10, 2016, Nasdaq.com published: “NewLink Genetics Awarded $25 Million Contract from BARDA for Investigational …” on October 04, 2016. More interesting news about NewLink Genetics Corp (NASDAQ:NLNK) were released by: Fool.com and their article: “Why NewLink Genetics Shares Are Crashing 33% Today” published on May 10, 2016 as well as Globenewswire.com‘s news article titled: “NewLink Genetics Corporation Appoints Brian Wiley as Chief Commercial Officer” with publication date: January 08, 2016.
NLNK Company Profile
NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a biopharmaceutical firm focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. The Company’s biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. The Company’s additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additional product candidates are also under development for patients with other types of cancer. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod, which target key immune checkpoints. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.